137 related articles for article (PubMed ID: 15183345)
1. Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets.
Ohtaka H; Muzammil S; Schön A; Velazquez-Campoy A; Vega S; Freire E
Int J Biochem Cell Biol; 2004 Sep; 36(9):1787-99. PubMed ID: 15183345
[TBL] [Abstract][Full Text] [Related]
2. Adaptive inhibitors of the HIV-1 protease.
Ohtaka H; Freire E
Prog Biophys Mol Biol; 2005 Jun; 88(2):193-208. PubMed ID: 15572155
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
Ohtaka H; Schön A; Freire E
Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
[TBL] [Abstract][Full Text] [Related]
4. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
5. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
Velazquez-Campoy A; Kiso Y; Freire E
Arch Biochem Biophys; 2001 Jun; 390(2):169-75. PubMed ID: 11396919
[TBL] [Abstract][Full Text] [Related]
6. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
7. Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease.
Böttcher J; Blum A; Heine A; Diederich WE; Klebe G
J Mol Biol; 2008 Nov; 383(2):347-57. PubMed ID: 18692068
[TBL] [Abstract][Full Text] [Related]
8. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
[TBL] [Abstract][Full Text] [Related]
9. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.
Cihlar T; He GX; Liu X; Chen JM; Hatada M; Swaminathan S; McDermott MJ; Yang ZY; Mulato AS; Chen X; Leavitt SA; Stray KM; Lee WA
J Mol Biol; 2006 Oct; 363(3):635-47. PubMed ID: 16979654
[TBL] [Abstract][Full Text] [Related]
10. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
Alcaro S; Artese A; Ceccherini-Silberstein F; Ortuso F; Perno CF; Sing T; Svicher V
J Chem Inf Model; 2009 Jul; 49(7):1751-61. PubMed ID: 19537723
[TBL] [Abstract][Full Text] [Related]
12. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
14. Genotype dependent QSAR for HIV-1 protease inhibition.
Boutton CW; De Bondt HL; De Jonge MR
J Med Chem; 2005 Mar; 48(6):2115-20. PubMed ID: 15771454
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
Torti C; Quiros-Roldan E; Monno L; Patroni A; Saracino A; Angarano G; Tinelli C; Lo Caputo S; Tirelli V; Mazzotta F; Carosi G; ;
J Med Virol; 2004 Sep; 74(1):29-33. PubMed ID: 15258965
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
[TBL] [Abstract][Full Text] [Related]
18. Protease inhibition in African subtypes of HIV-1.
Velázquez-Campoy A; Vega S; Fleming E; Bacha U; Sayed Y; Dirr HW; Freire E
AIDS Rev; 2003; 5(3):165-71. PubMed ID: 14598565
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
Clemente JC; Robbins A; Graña P; Paleo MR; Correa JF; Villaverde MC; Sardina FJ; Govindasamy L; Agbandje-McKenna M; McKenna R; Dunn BM; Sussman F
J Med Chem; 2008 Feb; 51(4):852-60. PubMed ID: 18215016
[TBL] [Abstract][Full Text] [Related]
20. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
Hou T; Yu R
J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
